Exclusive Summary

• As a classic off-patent generic, it targets a highly stable global market driven by the rigid demand of over 200 million patients with Peripheral Arterial Disease (PAD).
• Compared to heavily saturated oral tablets, the 5ml:0.1g injection formulation meets the critical clinical needs of hospitalized patients requiring rapid microcirculation improvement.
• The sterile manufacturing barrier of injections, combined with China's mass-production supply chain, guarantees distributors highly competitive procurement costs and lucrative profit margins.
• Comprehensive regulatory support with international QMS standards and ready-to-submit CTD dossiers significantly accelerates the local registration process for distribution partners.